Literature DB >> 26492512

Adaptive immune response to therapy in hmgcr autoantibody myopathy.

John S Yi1, Melissa A Russo2, Kent J Weinhold1, Jeffrey T Guptill2.   

Abstract

INTRODUCTION: We evaluated the response to immunosuppression in a case of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)-autoantibody myopathy.
METHODS: T- and B-cell subsets were determined by flow cytometry pre- and posttherapy.
RESULTS: Baseline immune profiling demonstrated strikingly elevated T-follicular helper (Tfh) cells and plasmablasts. Immunosuppression resulted in clinical improvement and decreased Tfh cells, plasmablasts, and autoantibodies.
CONCLUSIONS: Immune profiling in HMGCR-autoantibody myopathy suggests a B-cell-mediated disease. Tfh cells and plasmablasts may be therapeutic biomarkers.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  B-cells; B-lymphocytes; HMGCR protein; T-cells; T-lymphocytes; autoimmunity; human; immune suppression; inflammatory myopathy

Mesh：

Substances：

Year:  2015        PMID： 26492512      PMCID： PMC4718836          DOI： 10.1002/mus.24947

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  18 in total

1.  Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.

Authors:  C E Jackson; R J Barohn; G Gronseth; S Pandya; L Herbelin
Journal:  Muscle Nerve       Date:  2008-04       Impact factor: 3.217

Review 2.  Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation.

Authors:  Nikhil S Joshi; Susan M Kaech
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 3.  Paths to stemness: building the ultimate antitumour T cell.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 4.  Abnormalities of B cell subsets in patients with systemic lupus erythematosus.

Authors:  Thomas Dörner; Annett M Jacobi; Jisoo Lee; Peter E Lipsky
Journal:  J Immunol Methods       Date:  2010-06-17       Impact factor: 2.303

5.  Progressive myopathy with up-regulation of MHC-I associated with statin therapy.

Authors:  Merrilee Needham; Victoria Fabian; Wally Knezevic; Peter Panegyres; Paul Zilko; Frank L Mastaglia
Journal:  Neuromuscul Disord       Date:  2007-01-22       Impact factor: 4.296

6.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Jessie L Werner; Lisa Christopher-Stine; Sharon R Ghazarian; Katherine S Pak; Jordan E Kus; Natalie R Daya; Thomas E Lloyd; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2012-12

7.  Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.

Authors:  Rimpei Morita; Nathalie Schmitt; Salah-Eddine Bentebibel; Rajaram Ranganathan; Laure Bourdery; Gerard Zurawski; Emile Foucat; Melissa Dullaers; SangKon Oh; Natalie Sabzghabaei; Elizabeth M Lavecchio; Marilynn Punaro; Virginia Pascual; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2011-01-06       Impact factor: 31.745

8.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

9.  Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Authors:  Jeffrey T Guptill; John S Yi; Donald B Sanders; Amanda C Guidon; Vern C Juel; Janice M Massey; James F Howard; Flavia Scuderi; Emanuela Bartoccioni; Amelia Evoli; Kent J Weinhold
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-26

10.  Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production.

Authors:  Konstantia-Maria Chavele; Eve Merry; Michael R Ehrenstein
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.